Loading clinical trials...
Loading clinical trials...
This phase IIb study is designed to determine the safe and efficacious dose or dose range of AFQ056 for the treatment of patients with moderate to severe Parkinson's disease with L-Dopa induced dyskin...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Novartis
NCT07187843 · Parkinson Disease, Parkinsonian Disorders, and more
NCT07545473 · Dementia, Neurodegenerative Diseases, and more
NCT07543861 · Parkinson Disease
NCT05748028 · Parkinson Disease, Multiple System Atrophy
NCT04876339 · Parkinson Disease, Stroke, and more
Novartis Investigative Site
East Gosford
Novartis Investigative Site
Heidelberg
Novartis Investigative Site
Melbourne
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions